23 Results for "

organ inflammation

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "organ inflammation" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-14744A
CAS No.: 150566-71-5
Purity:  99.84%
Synonyms: (S)-Amlodipine besylate; Levoamlodipine besylate
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease

Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14744
CAS No.: 103129-82-4
Purity:  98.53%
Synonyms: (S)-Amlodipine; Levoamlodipine
Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-161834
CAS No.: 2140901-88-6
RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W011215
CAS No.: 84-75-3
Dihexyl phthalate is an orally active phthalate ester (PAEs) widely used as a plasticizer, and it acts as an environmental endocrine disruptor. Dihexyl phthalate exhibits endocrine-disrupting and reproductive toxic properties, induces oxidative stress and inflammation, and ultimately causes apoptosis and damage to reproductive organs such as the testes. Dihexyl phthalate can be used in studies related to developmental toxicity, embryonic lethality, teratogenicity, and abnormal development of the male reproductive system .
loading...
    loading...
Cat. No.: HY-178129
CAS No.: 1312534-69-2
Target:  

Syk

Research Areas:  

Inflammation/Immunology

MRL-SYKi is a chemical probe for gain-of-function variants of spleen tyrosine kinase (SYK). MRL-SYKi reduces the catalytic activity of SYK S550Y, SYK S550F and SYK P342T, and downregulates the phosphorylation level of SYK S550Y. MRL-SYKi serves as a template for developing NanoBRET tracers targeting SYK, enabling NanoBRET cellular target engagement assays for gain-of-function variants of SYK. MRL-SYKi is applicable to research related to inflammatory and immune diseases .
loading...
    loading...
Cat. No.: HY-119171
CAS No.: 1953157-39-5
Purity:  99.80%
Target:  

KMO

GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMO’s substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H2O2) production and reduces H2O2 levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-W010934
CAS No.: 1253-84-5
3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
loading...
    loading...
Cat. No.: HY-162866
Target:  

Autophagy

Research Areas:  

Metabolic Disease

CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .
loading...
    loading...
Cat. No.: HY-N7372
CAS No.: 66067-26-3
Licoisoflavanone is an orally active isoflavane-based immunomodulator with multiple activities including antiviral, anti-inflammatory, cytoprotective and cancer cell apoptosis-inducing effects. Licoisoflavanone can be isolated from the roots and rhizomes of Glycyrrhiza uralensis Fisch. Licoisoflavanone not only enhances the body's immunity, but also effectively prevents acute respiratory distress syndrome and multiple organ damage by alleviating cytokine storm, thereby reducing the degree of inflammation. In rats, Licoisoflavanone undergoes multiple metabolic transformation processes such as glucuronidation, hydroxylation, sulfation, methylation and dehydrogenation. Licoisoflavanone has become an important candidate molecule for research on COVID-19 and related inflammatory diseases .
loading...
    loading...
Cat. No.: HY-B1230
CAS No.: 54-30-8
Target:  

mAChR

Research Areas:  

Inflammation/Immunology

Camylofine is an antispasmodic agent with myogenic and neurogenic effects. Camylofine exhibits mild anticholinergic activity and blocks the M3 receptors on colonic smooth muscle. Camylofine dihydrochloride inhibits phosphodiesterase, elevates intracellular cAMP levels and reduces intracellular Ca 2+ levels, thereby promoting smooth muscle relaxation. Camylofine can be used in studies related to antispasmodia, gastrointestinal smooth muscle and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-P4984
CAS No.: 137593-46-5
Target:  

Endogenous Metabolite

Research Areas:  

Infection

Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a superantigen exotoxin produced by Staphylococcus aureus. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) binds to TCR and MHC II outside the antigen-presenting site, thereby inducing unconventional polyclonal lymphocyte activation, excessive cytokine production, rapid shock, multiple organ failure syndrome and even death. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) exacerbates mammary gland inflammation and further induces mastitis. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is thermostable and can be transmitted to humans via food, causing toxic shock syndrome. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in studies related to toxic shock syndrome and staphylococcal food poisoning .
loading...
    loading...
Cat. No.: HY-W011215S
CAS No.: 1015854-55-3
Dihexyl phthalate-3,4,5,6-d4 is the deuterated-labeled Dihexyl phthalate (HY-W011215). Dihexyl phthalate is an orally active phthalate ester (PAEs) widely used as a plasticizer, and it acts as an environmental endocrine disruptor. Dihexyl phthalate exhibits endocrine-disrupting and reproductive toxic properties, induces oxidative stress and inflammation, and ultimately causes apoptosis and damage to reproductive organs such as the testes. Dihexyl phthalate can be used in studies related to developmental toxicity, embryonic lethality, teratogenicity, and abnormal development of the male reproductive system .
loading...
    loading...
Cat. No.: HY-14744D
CAS No.: 884648-62-8
Levamlodipine besylate Hemipentahydrate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate Hemipentahydrate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate Hemipentahydrate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate Hemipentahydrate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate Hemipentahydrate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate Hemipentahydrate can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-119681
CAS No.: 79889-39-7
Target:  

Others

Research Areas:  

Inflammation/Immunology

YM 11124 is an orally active selective immunosuppressive agent. YM 11124 can inhibit cell-mediated immune responses (type IV allergic reactions, such as delayed-type hypersensitivity and allogenic skin graft rejection) and type III allergic reactions (such as passive Arthus reaction). YM 11124 has no effect on type I, type II allergic reactions or acute inflammation. YM 11124 can be used in research related to organ transplantation and immune hypersensitivity .
loading...
    loading...
Cat. No.: HY-14744B
CAS No.: 865430-76-8
Synonyms: (S)-Amlodipine hydrochloride; Levoamlodipine hydrochloride
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease

Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-B1230A
CAS No.: 5892-41-1
Target:  

mAChR

Research Areas:  

Inflammation/Immunology

Camylofine dihydrochloride is an antispasmodic agent with myogenic and neurogenic effects. Camylofine dihydrochloride exhibits mild anticholinergic activity and blocks the M3 receptors on colonic smooth muscle. Camylofine dihydrochloride inhibits phosphodiesterase, elevates intracellular cAMP levels and reduces intracellular Ca 2+ levels, thereby promoting smooth muscle relaxation. Camylofine dihydrochloride can be used in studies related to antispasmodia, gastrointestinal smooth muscle and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-14744S
CAS No.: 1346617-19-3
Purity:  99.74%
Synonyms: (S)-Amlodipine-d4; Levoamlodipine-d4
Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-14744C
CAS No.: 865430-78-0
Synonyms: (S)-Amlodipine hydrobromide; Levoamlodipine hydrobromide
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease Others

Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrobromide is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrobromide significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrobromide not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrobromide exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrobromide may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrobromide can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
Cat. No.: HY-L185
2,568 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Cat. No.: HY-D3197
CDg16 is a selective fluorescent dye targeting SLC18B1 (λabsem=458/544 nm) that is actively transported into lysosomal vesicles of activated macrophages independent of the endocytic pathway. CDg16 enables highly specific vesicle localization in live cells. CDg16 exhibits no cytotoxicity and accurately distinguishes activated M1 and M2 subsets from different origins. CDg16 shows low background staining in non-activated cells and normal organs, making it suitable for time-lapse imaging. In preclinical animal models of inflammatory sites, atherosclerotic plaques and liver inflammation, CDg16 allows visualization of activated macrophages. CDg16 can be used to study inflammation-related diseases and atherosclerosis .
loading...
    loading...